e18533 Background: Radioimmunotherapy is an effective and increasingly used option for patients with B-cell lymphomas. Particularly in the relapsed/refractory setting, patients may have sizable disease limited to one or a few sites. Many patients are heavily pretreated, with a subsequent downregulation of CD20 expression on the surface of lymphoma cells. Emerging evidence suggests a role for radiation to upregulate CD20 expression, which could sensitize the irradiated lymphoma cells to radioimmunotherapy.
PMID: 28023286 [PubMed - in process]